HealthLinx's Cancer Test on Market Soon (Australia)
This article was originally published in PharmAsia News
Healthlinx Ltd., one of Australia's leading diagnostics developers, hopes to market a new blood test for ovarian cancer by the second quarter of 2008. The new testing method, called OvPlex, recently showed promising results during a Phase II clinical trial. OvPlex measures five different biomarkers in the blood, making it more sensitive and more accurate than most of those currently on the market. The company hopes to make it available domestically as well as submitting it for approval in the United States, Asia, and Europe. (Click here for more - May Require Free Registration
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.